Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC Study.

Cattedra di Igiene dell'Università di Brescia, Italy.
Hepatology (Impact Factor: 11.19). 09/1997; 26(3):579-84. DOI: 10.1002/hep.510260308
Source: PubMed

ABSTRACT We performed a case-control study to assess the association of hepatocellular carcinoma (HCC) with hepatitis B virus (HBV) and hepatitis C virus (HCV) infection and alcohol drinking. We recruited as cases 172 subjects with an initial diagnosis of HCC, who were admitted to the two major hospitals in the province of Brescia, northern Italy, and 332 subjects, sex-, age-, and hospital-matched, who were admitted to the Departments of Ophthalmology, Dermatology, Urology, Cardiology, and Internal Medicine, as controls. Of the HCC cases, 23.8% were positive for HBsAg and 37.8% for HCV RNA; among the controls, 5.4% were positive for HBsAg and 4.8% for HCV RNA. History of heavy alcohol intake (>80 g of ethanol per day for at least 5 years) was found among 58.1% of the cases and among 36.4% of the controls. The relative risks (RRs) for HBsAg, HCV RNA positivity, and heavy alcohol intake were, respectively: 11.4 (95% confidence interval: 5.7-22.8), 23.2 (95% confidence interval: 11.8-45.7), and 4.6 (95% confidence interval: 2.7-7.8). Positive interactions (synergisms) between both HBsAg positivity and HCV RNA positivity and heavy alcohol intake were found, suggesting more than additive effects of viral infections and alcohol drinking on the risk of HCC. Infection with HCV genotype 1b showed a higher risk than type 2 (RR = 2.9; 95% confidence interval: 0.9-10), suggesting a major role for the former type in causing HCC. On the basis of population attributable risks (AR), heavy alcohol intake seems to be the single most relevant cause of HCC in this area (AR: 45%), followed by HCV (AR: 36%), and HBV (AR: 22%) infection.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Transgenic mice expressing the full-length HCV coding sequence were crossed with mice that express the HBV X gene-encoded regulatory protein HBx (ATX mice) to test the hypothesis that HBx expression accelerates HCV-induced liver pathogenesis. At 16 months (mo) of age, hepatocellular carcinoma was identified in 21% of HCV/ATX mice, but in none of the single transgenic animals. Analysis of 8-mo animals revealed that, relative to HCV/WT mice, HCV/ATX mice had more severe steatosis, greater liver-to-body weight ratios, and a significant increase in the percentage of hepatocytes staining for proliferating cell nuclear antigen. Furthermore, primary hepatocytes from HCV, ATX, and HCV/ATX transgenic mice were more resistant to fas-mediated apoptosis than hepatocytes from nontransgenic littermates. These results indicate that HBx expression contributes to increased liver pathogenesis in HCV transgenic mice by a mechanism that involves an imbalance in hepatocyte death and regeneration within the context of severe steatosis.
    Virology 05/2006; 347(2):466-75. DOI:10.1016/j.virol.2005.11.050 · 3.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Polyinosinic polycytidylic acid (poly I:C) is an analog of double stranded RNA, which is a common replication intermediate for many viruses. It acts through a toll-like receptor (TLR3) to induce a group of cytokines that can mediate host resistance to viruses and some cancers. The effect of ethanol (EtOH) on induction of this set of cytokines has not been determined. Mice were treated with a single dose of EtOH (by gavage) at the same time as poly I:C was administered (intraperitoneally), and cytokine mRNA expression was measured by RNAse protection assay. Concentrations of IFN-alpha, IL-10, and IL-12 in the serum were measured by ELISA. A single dose of EtOH suppressed induction of mRNA for IFN-alpha, IFN-beta, IFN-gamma, IL-6, IL-9, IL-12, and IL-15. The concentrations of IFN-alpha and IL-12 in the serum were also decreased. In contrast, IL-10 was minimally induced by poly I:C alone, but it was substantially induced by poly I:C plus EtOH. Dose response and time course studies demonstrated that significant alterations of IFN-alpha, IL-10, and IL-12 expression occurred at dosages as low as 4 g/kg (a dosage previously shown to produce blood EtOH concentrations of approximately 0.2%) and that alterations persisted at least 4-6 hr after administration of EtOH. The glucocorticoid synthesis inhibitor, aminoglutethimide, diminished corticosterone levels to normal, but did not block the effects of EtOH on cytokine expression. These results demonstrate that EtOH affects the expression of poly I:C-induced cytokines and that this action is not mediated by corticosterone. These results plus previously published findings are consistent with the idea that EtOH may be a generalized suppressor of toll-like receptor signaling.
    Life Sciences 04/2003; 72(16):1825-39. DOI:10.1016/S0024-3205(02)02507-9 · 2.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic hepatitis C is frequently seen in HIV-positive subjects infected through needle sharing or transfusion of contaminated blood products. Progression to end-stage liver disease seems to occur faster in these patients. As the life expectancy of HIV-infected persons has dramatically improved since the introduction of highly active antiretroviral therapies, cirrhosis and eventually hepatocellular carcinoma (HCC) may be recognized at an increasing rate in patients coinfected with HIV and hepatitis C virus (HCV). We identified the main features of HIV-infected individuals with end-stage liver disease due to HCV infection and diagnosed with HCC in three HIV/AIDS referral centers, and compared these features to those of a control group of patients with HCV-related HCC but without HIV infection. Seven HIV-infected patients were identified. Of these, six were <45 yr of age and had been intravenous drug users. The mean time between exposure to HCV and the development of HCC was estimated to be 17.8 yr. Two subjects were coinfected with hepatitis B and delta viruses, respectively. Only one individual had been diagnosed of an AIDS-defining condition before the diagnosis of HCC was made. However, all subjects had < 500 CD4+ T cells at the time of HCC diagnosis. Five died within the first 4 months of follow-up. Patients in the control group (n = 31) were significantly older (68.9 +/- 8.9 vs 42.2 +/- 10.4; p < 0.001) and the duration of HCV infection was significantly longer (28.1 +/- 10.9 vs 17.8 +/- 2.7; p < 0.05) than in those with HIV-HCV coinfection. HCC seems to occur at a younger age and after a shorter period of HCV infection in subjects coinfected with HIV. Thus, treatment of CHC should be encouraged in HIV-positive patients, and in those with HCV-related cirrhosis the periodic monitoring of alpha-fetoprotein and abdominal ultrasonography should be recommended.
    The American Journal of Gastroenterology 01/2001; 96(1):179-83. DOI:10.1111/j.1572-0241.2001.03374.x · 9.21 Impact Factor


1 Download